MHRA Drug Safety Alert: Dorzolomide hydrochloride/timolol maleate (Cosopt) preservative-free single-dose eye drops: reports of eye injury
Dorzolomide hydrochloride/timolol maleate (Cosopt) preservative-free single-dose eye drops are used to treat glaucoma. The MHRA is aware of 69 complaints in the UK with this product after the introduction of a new design of dropper in July 2013. These reports include scratches to the cornea, and difficulty in administration of the drops onto the eye.
Response to NICE announcing their positive draft guidance for Eylea® for the treatment of macular oedema secondary to CRVO
College Statement The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). We hope that this decision will help the clinical commissioning groups to support the rapid implementation of the final